Home-infusion-therapy

Register to receive a free US Infusion Therapy Device Market report synopsis and brochure

A new study by the CVS Health Research Institute found that home infusion care is safe, clinically effective and improves quality of life while reducing health care costs when compared to infusion care delivered in a hospital or clinic. The findings underscore the value of home infusion services – where medication is delivered intravenously in a patient’s home – for the health care system, including patients and payers. The study was published in Healthcare: The Journal of Delivery Science and Innovation.

“As the U.S. health care payment system shifts from volume to value, we are focused on identifying new approaches to health service delivery that provide better care and improve patient outcomes while lowering costs,” said Troyen A. Brennan, MD, study author and Chief Medical Officer, CVS Health. “Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.”

Researchers conducted a systematic review of existing peer-reviewed research evaluating infusion care for several conditions, including cystic fibrosis, antibiotics following orthopedic surgery and several cancers requiring infused chemotherapies. Researchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings. The research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting. In addition, patients overwhelmingly preferred receiving their infusion therapies at home, reporting fewer disruptions in personal schedules and responsibilities. The costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.

“At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,” added Alan Lotvin, MD, Executive Vice President, CVS Specialty. “In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.”

Home infusion services are a rapidly growing delivery model in the health care system with rising rates of chronic and acute conditions that require intravenous therapy. Despite this, clinical outcomes and quality of care have not previously been systematically evaluated. While many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.

Coram, a service provided by CVS Health, provides vital infusion care and support to tens of thousands of Americans each month with a range of conditions including immune deficiencies, rheumatoid arthritis and serious infections requiring intravenous antibiotic therapy. Care is administered by experienced infusion nurses and pharmacists, and in addition, patients receive additional disease management education and support throughout their treatment.

The CVS Health Research Institute is focused on contributing to the body of scientific knowledge related to pharmacy and health care through research collaborations with external academic institutions, participation in federally-funded research, analysis and sharing of CVS Health data sources and coordination of pilot programs and initiatives. CVS Health Research Institute findings support a continuous quality improvement environment, which encourages product innovation and development to benefit CVS Health patients, clients and their members.

For Further Information
More on the markets for infusion therapy devices in the U.S. can be found in this 2015 edition report published by iData entitled U.S. Market for Infusion Therapy Devices, which covers the U.S. as a whole, as well as market segments for large volume, syringe, patient-controlled analgesia, electronic ambulatory, and disposable ambulatory infusion pumps; primary, secondary and extension IV sets; and split septum, blunt cannula, and mechanical valve needleless connectors.

The iData series on the market for infusion therapy devices also covers the U.S., Australia, Japan, South Korea, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. Register online or email us at [email protected] for an U.S. Market for Infusion Therapy Devices report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch